论文部分内容阅读
目的观察氯吡格雷治疗高龄老年冠心病患者的安全性。方法将入选口服氯吡格雷的患者按年龄分为3组:高龄老年组70例,年龄≥80岁,平均84.50±8.16岁;老年组60例,年龄60～79岁,平均76.50±7.16岁;对照组82例,年龄≤59岁,平均56.50±3.16岁。分别口服氯吡格雷75mg/d后6个月、12个月检测肝功、肾功、血小板计数、白细胞计数和中性粒细胞计数及血脂的变化,并观察各组发生胃肠道出血及其他不良反应,比较高龄老年组、老年组和对照组患者口服氯吡格雷的安全性。结果治疗前后3组患者肝功、肾功、血小板计数、白细胞计数、中性粒细胞计数结果差异无统计学意义(P>0.05)。3组患者均同时服用他汀类调脂药,总胆固醇和低密度脂蛋白胆固醇治疗后6个月、12个月低于治疗前(P<0.05),而治疗后6个月与治疗后12个月结果变化无统计学意义(P>0.05)。3组消化道出血的发生率无统计学意义(P>0.05)。结论高龄老年冠心病患者口服氯吡格雷安全性较好。
Objective To observe the safety of clopidogrel in elderly patients with coronary heart disease. Methods Patients with oral clopidogrel were divided into three groups according to their age: 70 in the elderly group, with a mean age of 84.50 ± 8.16 years; the elderly group of 60 patients aged from 60 to 79 years with an average of 76.50 ± 7.16 years; The control group of 82 cases, aged ≤ 59 years, mean 56.50 ± 3.16 years. The changes of liver function, renal function, platelet count, white blood cell count, neutrophil count and blood lipids were measured at 6 and 12 months after oral administration of clopidogrel 75 mg / d respectively. Gastrointestinal bleeding and other Adverse reactions, compared with the elderly elderly group, elderly patients and control group oral clopidogrel safety. Results There was no significant difference in liver function, renal function, platelet count, white blood cell count and neutrophil count in the three groups before and after treatment (P> 0.05). Three groups of patients took statin lipid-lowering drugs at the same time. The levels of total cholesterol and low-density lipoprotein cholesterol were lower in 6 months and 12 months than those before treatment (P <0.05), and 6 months and 12 months after treatment There was no significant difference in monthly results (P> 0.05). The incidence of gastrointestinal bleeding in 3 groups was not statistically significant (P> 0.05). Conclusion Clopidogrel is safe in elderly patients with coronary heart disease.